Antibody-Drug Conjugate Shows Promise for EGFR NSCLC
Summary of Iza-bren Study Results in EGFR-Mutated NSCLC
this article reports promising early data on iza-bren, a new treatment being investigated for advanced or metastatic solid tumors, especially EGFR-mutated Non-Small Cell Lung Cancer (NSCLC).Key findings:
subgroup Analysis (TKI-naive,prior chemo-naive patients): A subgroup of 50 patients with EGFR-mutated NSCLC who had previously received a TKI but were chemotherapy-naive,and treated with 2.5 mg/kg of iza-bren on a D1D8 Q3W schedule, showed:
objective Response Rate (ORR): 66.0%
Confirmed Objective Response Rate (cORR): 56.0%
Median Progression-Free Survival (mPFS): 12.5 months
Median Duration of Response (mDOR): 13.7 months
Median Overall Survival (mOS): Not reached (12-month OS rate of 80.3%)
Safety: The treatment was considered to have a manageable safety profile. Common side effects included anemia, leukopenia, neutropenia, thrombocytopenia, nausea, alopecia, and asthenia. Discontinuation due to side effects was low (1.2%), and no treatment-related deaths were reported.
Ongoing Research: A Phase III registrational study is underway in China to evaluate iza-bren as a monotherapy for EGFR-mutated NSCLC patients who have progressed after treatment with a third-generation TKI.
Dr. Wenfeng Fang suggests that iza-bren appears to be a promising new treatment option for patients with EGFR-mutated NSCLC.